FDA approval of generic Lovenox sparks debate and lawsuit
This article was originally published in Scrip
Executive Summary
The US FDA approval of the first generic version of Sanofi-Aventis's Lovenox (enoxaparin sodium) to Novartis' generics arm Sandoz, which uses technology from Momenta Pharmaceuticals, has caused a buzz because the agency has treated the application like a standard but yet complicated ANDA and did not require full clinical studies.
You may also be interested in...
The Blockbusters No One Talks About
Drugs like Nexium, Lipitor, Lovenox and Plavix lost patent protection years ago, but continue to generate blockbuster level sales. Here's a look at the blockbuster brands that have stood the test of (generic) time.
The Blockbusters No One Talks About
Drugs like Nexium, Lipitor, Lovenox and Plavix lost patent protection years ago, but continue to generate blockbuster level sales. Here's a look at the blockbuster brands that have stood the test of (generic) time.
ChemoCentryx cuts price to get $45M IPO away
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).